SOLESENCE, INC.

Solésence, Inc. (SLSN) received a notification from Nasdaq indicating that its common stock is not in compliance with the minimum bid price requirement of $1.00 per share, as the closing bid price has fallen below this threshold for 30 consecutive trading days. The company has been granted an initial compliance period of 180 days, until March 29, 2027, to meet the requirement. Solésence is exploring options to regain compliance, but there is no guarantee of success. The notice does not immediately affect the stock's listing or the company's SEC reporting obligations.

Solésence, Inc. has announced the rescheduling of its second quarter 2026 conference call and webcast. The call, originally planned earlier, will now take place on Wednesday, August 19, 2026, at 5:00 p.m. ET. This adjustment provides additional time for the company to finalize its quarterly financial reporting and review processes.

Solésence, Inc. announced the launch of two new market-ready products: Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen. These products expand the company's presence in the fast-growing hair and scalp care segment, leveraging proprietary WHSPR™ and Kleair™ technologies. The Scalp Screen Dry Shampoo was also named a finalist for the 2026 Cosmopack Award for Best Formulation, highlighting its innovative formulation. This launch aligns with Solésence's Transform and Transcend initiative, focusing on differentiated formulations for high-growth beauty segments.

Solésence, Inc.'s wholly owned subsidiary, Solésence, LLC, has entered into a Settlement Agreement and Release with Refy Beauty Ltd. to resolve disputes concerning previously sold consumer care products. Under the agreement, Solésence will pay Refy the British Pound Sterling equivalent of $938,000 in twelve equal monthly installments, with the first payment due on August 5, 2026. The parties also agreed to a six-month exclusivity period for the development of a new SPF product, with the potential for the final six installment payments to be credited towards a new supply agreement for this product.

Solésence, Inc. has been named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards, recognizing its excellence in client satisfaction, innovation, product development, and speed-to-market. This latest accolade adds to the 12 industry awards the company has received since 2022. Solésence plans to further expand its platform by launching new technologies in skin health and healing, moving into active skin restoration with its ingredient-led, patent-backed innovations.

Solésence, Inc. announced its prototype product, Day Mode Hero Concealer SPF 50+, won three categories at the 2026 Cosmetics & Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin. This achievement marks the company's fourth consecutive year of recognition at these prestigious awards. The concealer utilizes proprietary Solésence technologies, including Kleair , WHSPR , and Chromalüm , to deliver broad-spectrum SPF 50+ and skin health benefits, pushing boundaries across skincare, sun care, and makeup categories.

Solésence, Inc. announced its support for the recommendations in "A Preventable Crisis: The Case for a National UV Safety Strategy," a landmark report led by the U.K.'s All-Party Parliamentary Group (APPG) for Beauty, Hair & Wellbeing. The report, launched on May 13, highlights the U.K.'s lack of a cohesive national strategy to mitigate UV radiation, a Group 1 carcinogen, with melanoma cases projected to rise by 9% by 2038. Solésence, a member of the UV Safety Coalition, is committed to raising awareness and supporting comprehensive UV protection campaigns to drive daily protection behaviors.

Solésence, Inc. reported a decrease in total revenue for the first quarter of 2026, falling 11.4% to $12.96 million from $14.63 million in the prior year. The company also shifted from a net income of $0.08 million in Q1 2025 to a net loss of $0.77 million in Q1 2026, resulting in a basic and diluted loss per share of $0.01. Despite the revenue decline and net loss, net cash provided by operating activities significantly improved to $1.52 million, compared to a use of $7.22 million in the same period last year.

Solésence, Inc. reported its first quarter 2026 financial results, with revenue decreasing to $13.0 million from $14.6 million in the prior year period. The company recorded a net loss of $0.8 million, a shift from a net income of $0.08 million in Q1 2025. Despite the revenue decline and net loss, Solésence improved its gross margin to 26% from 23%, attributing this to disciplined execution of its "Transform and Transcend" strategic initiative focused on operational excellence. The company also highlighted the commercialization of new platform technologies and the addition of a new independent director.

Solésence, Inc. announced the commercial availability of two new proprietary platform technologies, WHSPR™ and Chromalüm™, significantly expanding its ingredient technology portfolio. WHSPR™ enables OTC-grade sensitive skin claims in previously inaccessible anhydrous formats, with clinical studies showing significant improvements in skin barrier recovery, hydration, and redness reduction. Chromalüm™ integrates broad-spectrum sun protection, including targeted high-energy visible (HEV) light protection, into color cosmetics without compromising aesthetic performance. These innovations reinforce Solésence's vertically integrated model, allowing brand partners to access differentiated product claims and expand category reach.